RGNX - REGENXBIO Inc.
IEX Last Trade
7.475
-0.025 -0.334%
Share volume: 6,598
Last Updated: Fri 27 Dec 2024 05:30:13 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.39%
PREVIOUS CLOSE
CHG
CHG%
$7.50
-0.03
-0.33%
Fundamental analysis
7%
Profitability
0%
Dept financing
11%
Liquidity
59%
Performance
1%
Performance
5 Days
0.27%
1 Month
-22.51%
3 Months
-30.71%
6 Months
-35.71%
1 Year
-60.53%
2 Year
-66.27%
Key data
Stock price
$7.48
DAY RANGE
$7.30 - $7.98
52 WEEK RANGE
$7.56 - $28.80
52 WEEK CHANGE
-$60.09
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
Company detail
CEO: Kenneth T. Mills
Region: US
Website: regenxbio.com
Employees: 370
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: regenxbio.com
Employees: 370
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
REGENXBIO Inc. provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells to produce therapeutic proteins or antibodies that are intended to impact disease. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration.
Recent news